Hengrui Pharmaceutical (600276.SH): HRS-6257 tablets approved to carry out clinical trials for post-operative analgesia

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that recently, the company's subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (“State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for HRS-6257 tablets, which will conduct clinical trials in the near future. According to reports, HRS-6257 tablets are intended to treat acute and chronic pain. According to inquiries, there are currently no drugs with the same target approved for marketing in China.